

APPLICANT(S): FRANKEL, Fred R et al.  
SERIAL NO.: 10/660,194  
FILED: September 11, 2003  
Page 2

### AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application the subject matter of claim 26 that is indicated as cancelled:

1-20. (Canceled)

21. (Previously Presented) A method of inducing an immune response against a cancer cell in a mammal, the method comprising administering to the mammal an auxotrophic attenuated strain of *Listeria* comprising an antigen expressed by the cancer cell.

22. (Currently Amended) The method of claim 21, wherein the auxotrophic attenuated strain of *Listeria* comprises a mutation in ~~both the dal gene and the dat gene~~.

23. (Previously Presented) The method of claim 21, wherein the antigen is expressed from a vector.

24. (Previously Presented) The method of claim 21, wherein the antigen is expressed from the *Listeria* genome.

25. (Previously Presented) The method of claim 21, wherein the auxotrophic attenuated strain of *Listeria* is administered orally, parenterally, intranasally, intramuscularly, intravascularly, intravenously, intrarectally or intraperitoneally.

26. (Currently Amended) The method of claim 21, wherein the cancer cell is a cervical cancer cell, ~~a melanoma cancer cell, a breast cancer cell, or a leukemia cancer cell.~~

APPLICANT(S): FRANKEL, Fred R et al.  
SERIAL NO.: 10/660,194  
FILED: September 11, 2003  
Page 3

27. (New) The method of claim 21, wherein the auxotrophic attenuated strain of *Listeria* comprises a mutation in the *dat* gene.

28. (New) The method of claim 27, wherein the auxotrophic attenuated strain of *Listeria* further comprises a mutation in the *dal* gene.

29. (New) The method of claim 21, wherein said *Listeria* is *L. monocytogenes*.